IP Library Granted Patent US 10,709,796
Granted Patent B2
US 10,709,796 · App. 15/651,698 · Granted Jul 14, 2020

Optimised coding sequence and promoter

Inventors: Amit Nathwani (London, GB); Natalie Ward (London, GB); Adrian Thrasher (London, GB); Edward Tuddenham (London, GB); John McVey (London, GB); John Gray (Memphis, TN); Andrew Davidoff (Memphis, TN)
Assignees: UCL BUSINESS PLC; THROMBOSIS RESEARCH INSTITUTE; ST. JUDE CHILDREN'S RESEARCH HOSPITAL
A61K48/0058A61K38/37C07K14/755C12N7/00C12N15/86A61K38/00C12N2710/10041C12N2710/14143C12N2750/14143C12N2800/22C12N2830/008
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,796
App. No.
15/651,698
Granted
Jul 14, 2020
Kind
B2
Abstract

An optimized coding sequence of human blood clotting factor eight (VIII) and a promoter may be used in vectors, such as rAAV, for introduction of factor VIII, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, and lipid storage diseases. Cells, vectors, proteins, and glycoproteins produced by cells transformed by the vectors and sequence, may be used in treatment.

Claims (6)

1. A recombinant adeno-associated virus (AAV) particle comprising a heterologous nucleic acid sequence and a liver-specific promoter that is operably linked to and drives expression of said heterologous nucleic acid sequence, wherein said promoter has at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:3 and is less than 350 base pairs in length.

2. The recombinant AAV particle of claim 1 , wherein said promoter comprises the nucleotide sequence of SEQ ID NO:3.

3. The recombinant AAV particle of claim 1 , wherein said promoter consists essentially of the nucleotide sequence of SEQ ID NO:3.

4. The recombinant AAV particle of claim 1 , wherein said promoter consists of the nucleotide sequence of SEQ ID NO:3.

5. The recombinant AAV particle of claim 1 which is of AAV5 serotype.

6. A composition of matter comprising the recombinant AAV particle of claim 1 and a pharmaceutically acceptable carrier.

Assignments (5)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
NAME CHANGE Recorded Aug 4, 2020
From: UCL BUSINESS PLC
To: UCL BUSINESS LTD
Reel/Frame 053397/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: NATHWANI, AMIT; WARD, NATALIE; THRASHER, ADRIAN; TUDDENHAM, EDWARD
To: UCL BUSINESS PLC
Reel/Frame 047830/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: MCVEY, JOHN
To: THROMBOSIS RESEARCH INSTITUTE
Reel/Frame 047830/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: GRAY, JOHN; DAVIDOFF, ANDREW
To: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Reel/Frame 047830/0350 →
Priority Claims (1)
GB 0911870.4 · Jul 8, 2009 · national
Continuity (3)
Continuation 14680836 · Apr 7, 2015
Division 13382953
Related Publication 20180008726A1 · Jan 11, 2018
Cited By (1)
US 12,257,319